Opko Invests in New Technologies, Raising Questions About the Company's Focus on RNAi | GenomeWeb

By Doug Macron

Although it bills itself primarily as an ophthalmic drug and instrumentation company, Opko Health has long been focused on the development of siRNA-based therapeutics, including the wet age-related macular degeneration treatment bevasiranib.

But with the failure of that drug in a phase III trial, Opko has lately been making investments in other technologies in earnest, raising questions about how much longer RNAi will remain as the centerpiece of the company's drug-development portfolio.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.